Actively Recruiting
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
Led by AbbVie · Updated on 2026-03-05
87
Participants Needed
2
Research Sites
92 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan. There will be 2 parts to this study. In Part 1, participants are placed in one of 3 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 3 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Approximately 87 adult participants will be enrolled at approximately 21 sites in the United States and Japan. Participants will be administered one dose of ABBV-547 or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
CONDITIONS
Official Title
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 55 years
- Generally good health based on medical history, physical exam, vital signs, lab tests, and ECG
- Part 1: Body mass index (BMI) between 18.0 and 29.9 kg/m² at screening
- Part 2: Discontinued phototherapy (UVA or UVB) at least 2 weeks before baseline visit
- Part 2: Discontinued PUVA phototherapy at least 4 weeks before baseline visit
You will not qualify if you...
- History of significant allergy or sensitivity to any medication or food
- Part 2: Use of herbal supplements within 2 weeks before study treatment
- Part 2: Received biologics or investigational agents within 2.5 half-lives before baseline
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CenExel ACT- Anaheim Clinical Trials /ID# 279612
Anaheim, California, United States, 92801
Actively Recruiting
2
Acpru /Id# 278638
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here